Showing results (191-200 of 290) with videos related to
Sort By:
Pageof 29
Clinical Genitourinary Cancer|August 5, 2014
Clinicopathologic outcomes of cystic renal cell carcinomaNicholas M Donin, Sanjay Mohan, Hai Pham, et al.BJU International|October 14, 2011
Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot studyHerbert Lepor, Carol D Cheli, Robert P Thiel, et al.The Journal of Urology|June 11, 2018
The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 YearsXiaosong Meng, Andrew B Rosenkrantz, Richard Huang, et al.Molecular Endocrinology (Baltimore, Md.)|September 1, 2007
Transcriptional regulation of the androgen receptor cofactor androgen receptor trapped clone-27Jerome C Nwachukwu, Wenhui Li, Inés Pineda-Torra, et al.Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.3D Printing in Medicine|February 21, 2019
Patient-specific 3D printed and augmented reality kidney and prostate cancer models: impact on patient educationNicole Wake, Andrew B Rosenkrantz, Richard Huang, et al.Urology|December 4, 2013
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal massesMarc A Bjurlin, Dawn Walter, Glen B Taksler, et al.Journal of Magnetic Resonance Imaging : JMRI|July 2, 2015
Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsyAndrew B Rosenkrantz, Xiaosong Meng, Justin M Ream, et al.European Urology Oncology|January 1, 2021
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysisArmando Stabile, Elio Mazzone, Giuseppe O Cirulli, et al.Contemporary Clinical Trials|June 19, 2007
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trialNeil Fleshner, Leonard G Gomella, Michael S Cookson, et al.Pageof 29